Literature DB >> 9119989

Cytotoxic T cells and viral hepatitis.

F V Chisari1.   

Abstract

Entities:  

Mesh：

Year:  1997        PMID： 9119989      PMCID： PMC507965          DOI： 10.1172/JCI119308

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  50 in total

1.  Up-regulation of MHC class I by flavivirus-induced peptide translocation into the endoplasmic reticulum.

Authors:  A Müllbacher; M Lobigs
Journal:  Immunity       Date:  1995-08       Impact factor: 31.745

2.  Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection.

Authors:  B Rehermann; C Pasquinelli; S M Mosier; F V Chisari
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

3.  Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant.

Authors:  A Weiner; A L Erickson; J Kansopon; K Crawford; E Muchmore; A L Hughes; M Houghton; C M Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

4.  The transactivator gene of human T-cell leukemia virus type I is more variable within and between healthy carriers than patients with tropical spastic paraparesis.

Authors:  S Niewiesk; S Daenke; C E Parker; G Taylor; J Weber; S Nightingale; C R Bangham
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

Review 5.  Hepatitis B virus immunopathogenesis.

Authors:  F V Chisari; C Ferrari
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

6.  Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C.

Authors:  G Ballardini; P Groff; P Pontisso; F Giostra; R Francesconi; M Lenzi; D Zauli; A Alberti; F B Bianchi
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

7.  Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection.

Authors:  M C Jung; H M Diepolder; U Spengler; E A Wierenga; R Zachoval; R M Hoffmann; D Eichenlaub; G Frösner; H Will; G R Pape
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

8.  Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules.

Authors:  M Battegay; J Fikes; A M Di Bisceglie; P A Wentworth; A Sette; E Celis; W M Ching; A Grakoui; C M Rice; K Kurokohchi
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

9.  Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif.

Authors:  A Cerny; J G McHutchison; C Pasquinelli; M E Brown; M A Brothers; B Grabscheid; P Fowler; M Houghton; F V Chisari
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

10.  Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.

Authors:  P R Galle; W J Hofmann; H Walczak; H Schaller; G Otto; W Stremmel; P H Krammer; L Runkel
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307
View more
  86 in total

1.  Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies.

Authors:  Yanfang Jiang; Wanyu Li; Lei Yu; Jingjing Liu; Guijie Xin; Hongqing Yan; Pinghui Sun; Hong Zhang; Damo Xu; Junqi Niu
Journal:  Cell Mol Immunol       Date:  2010-10-04       Impact factor: 11.530

Review 2.  Immune escape by hepatitis B viruses.

Authors:  U Protzer; H Schaller
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

3.  Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels.

Authors:  F Bolacchi; A Sinistro; C Ciaprini; F Demin; M Capozzi; F C Carducci; C M J Drapeau; G Rocchi; A Bergamini
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

4.  Apoptosis in chronic viral hepatitis parallels histological activity: an immunohistochemical investigation using anti-activated caspase-3 and M30 cytodeath antibody.

Authors:  Jo L McPartland; Muna Ali Guzail; Charles H Kendall; James Howard Pringle
Journal:  Int J Exp Pathol       Date:  2005-02       Impact factor: 1.925

5.  Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model.

Authors:  I-Tsu Chyuan; Hwei-Fang Tsai; Horng-Tay Tzeng; Chi-Chang Sung; Chien-Sheng Wu; Pei-Jer Chen; Ping-Ning Hsu
Journal:  Cell Mol Immunol       Date:  2015-02-09       Impact factor: 11.530

Review 6.  Pathogenesis of hepatitis B virus infection.

Authors:  Thomas F Baumert; Robert Thimme; Fritz von Weizsäcker
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

7.  DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection.

Authors:  C B Bigger; K M Brasky; R E Lanford
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  Characterization of nuclear RNases that cleave hepatitis B virus RNA near the La protein binding site.

Authors:  T Heise; L G Guidotti; F V Chisari
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

9.  HLA-DPB1 and anti-HBs titer kinetics in hepatitis B booster recipients who completed primary hepatitis B vaccination during infancy.

Authors:  T-W Wu; C-C Chu; H-W Chang Liao; S-K Lin; T-Y Ho; M Lin; H H Lin; L-Y Wang
Journal:  Genes Immun       Date:  2013-11-28       Impact factor: 2.676

10.  Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases.

Authors:  Hurng-Yi Wang; Ming-Hung Chien; Hsiang-Po Huang; Hsiao-Chi Chang; Chung-Che Wu; Pei-Jer Chen; Mei-Hwei Chang; Ding-Shinn Chen
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.